Zollinger-Ellison syndrome classification: Difference between revisions
Jump to navigation
Jump to search
| Line 13: | Line 13: | ||
*The WHO (2010) classified all neuroendocrine tumors, including [[Gastrinoma|gastrinomas]] into three grades based on the mitotic rate, or Ki-67 index: <ref name="urlGastrinoma - StatPearls - NCBI Bookshelf">{{cite web |url=https://www.ncbi.nlm.nih.gov/books/NBK441842/ |title=Gastrinoma - StatPearls - NCBI Bookshelf |format= |work= |accessdate=}}</ref> | *The WHO (2010) classified all neuroendocrine tumors, including [[Gastrinoma|gastrinomas]] into three grades based on the mitotic rate, or Ki-67 index: <ref name="urlGastrinoma - StatPearls - NCBI Bookshelf">{{cite web |url=https://www.ncbi.nlm.nih.gov/books/NBK441842/ |title=Gastrinoma - StatPearls - NCBI Bookshelf |format= |work= |accessdate=}}</ref> | ||
:{| class="wikitable" | :{| class="wikitable" | ||
!Grade | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Grade | ||
!Diffrentiation | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Diffrentiation | ||
!Mitotic range | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Mitotic range | ||
!Ki-67 index | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Ki-67 index | ||
!Behavior | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Behavior | ||
!WHO category | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |WHO category | ||
|- | |- | ||
|G1 | | style="background:#DCDCDC;" align="center" + |G1 | ||
|Low grade well-differentiated | | style="background:#F5F5F5;" + | Low grade well-differentiated | ||
|< 2 | | style="background:#F5F5F5;" + |< 2 | ||
|< 3% (10% to 30%) | | style="background:#F5F5F5;" + |< 3% (10% to 30%) | ||
|Uncertain | | style="background:#F5F5F5;" + |Uncertain | ||
|[[Neuroendocrine tumor]] | | style="background:#F5F5F5;" + |[[Neuroendocrine tumor]] | ||
|- | |- | ||
|G2 | | style="background:#DCDCDC;" align="center" + |G2 | ||
|Intermediate grade, well-differentiated | | style="background:#F5F5F5;" + |Intermediate grade, well-differentiated | ||
|2 to 20 | | style="background:#F5F5F5;" + |2 to 20 | ||
|3% to 20% (50% to 80%) | | style="background:#F5F5F5;" + |3% to 20% (50% to 80%) | ||
|Low-grade malignant | | style="background:#F5F5F5;" + |Low-grade malignant | ||
|[[Neuroendocrine tumor]] | | style="background:#F5F5F5;" + |[[Neuroendocrine tumor]] | ||
|- | |- | ||
|G3 | | style="background:#DCDCDC;" align="center" + |G3 | ||
|High grade, poorly differentiated | |High grade, poorly differentiated | ||
|> 20 | | style="background:#F5F5F5;" + |> 20 | ||
|> 20% (1% to 3%) | | style="background:#F5F5F5;" + |> 20% (1% to 3%) | ||
|High-grade malignant | | style="background:#F5F5F5;" + |High-grade malignant | ||
|[[Neuroendocrine]] carcinoma | | style="background:#F5F5F5;" + |[[Neuroendocrine]] carcinoma | ||
|} | |} | ||
*The following table illustrates the factors associated and the differences between sporadic and [[MEN-1]]-associated ZES: <ref name="pmid24319020">{{cite journal |vauthors=Epelboym I, Mazeh H |title=Zollinger-Ellison syndrome: classical considerations and current controversies |journal=Oncologist |volume=19 |issue=1 |pages=44–50 |year=2014 |pmid=24319020 |pmc=3903066 |doi=10.1634/theoncologist.2013-0369 |url=}}</ref> | *The following table illustrates the factors associated and the differences between sporadic and [[MEN-1]]-associated ZES: <ref name="pmid24319020">{{cite journal |vauthors=Epelboym I, Mazeh H |title=Zollinger-Ellison syndrome: classical considerations and current controversies |journal=Oncologist |volume=19 |issue=1 |pages=44–50 |year=2014 |pmid=24319020 |pmc=3903066 |doi=10.1634/theoncologist.2013-0369 |url=}}</ref> | ||
Revision as of 14:51, 18 March 2019
|
Zollinger-Ellison syndrome Microchapters |
|
Differentiating Zollinger-Ellison syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Zollinger-Ellison syndrome classification On the Web |
|
American Roentgen Ray Society Images of Zollinger-Ellison syndrome classification |
|
Risk calculators and risk factors for Zollinger-Ellison syndrome classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]
Overview
- According to the World Health Organization, neuroendocrine tumors (NETs) are classified into two broad categories namely, well differentiated and poorly differentiated. On the basis of histopathological analysis, most gastrinomas are considered well-differentiated neuroendocrine tumors (NETs).
Classiffication
- Gastrinomas are generally classified under the larger entity, "neuroendocrine tumors" (NETs).
- Among the enteroendocrine cells that arise from the embryologic endoderm, the gastrinomas are derived mainly from the pancreas, and also from the proximal small intestine. [1]
- According to the World Health Organization, neuroendocrine tumors (NETs) are classified into two broad categories; well differentiated, and poorly differentiated gastrinomas. On the basis of histopathological analysis, most of the gastrinomas are considered well-differentiated neuroendocrine tumors (NETs). [2]
- The WHO (2010) classified all neuroendocrine tumors, including gastrinomas into three grades based on the mitotic rate, or Ki-67 index: [3]
Grade Diffrentiation Mitotic range Ki-67 index Behavior WHO category G1 Low grade well-differentiated < 2 < 3% (10% to 30%) Uncertain Neuroendocrine tumor G2 Intermediate grade, well-differentiated 2 to 20 3% to 20% (50% to 80%) Low-grade malignant Neuroendocrine tumor G3 High grade, poorly differentiated > 20 > 20% (1% to 3%) High-grade malignant Neuroendocrine carcinoma
- The following table illustrates the factors associated and the differences between sporadic and MEN-1-associated ZES: [4]
| Sporadic and MEN-1-associated ZES | ||
| Factors | Sopradic ZES | MEN-1 ZES |
|---|---|---|
|
|
|
References
- ↑ Norton JA (1994). "Neuroendocrine tumors of the pancreas and duodenum". Curr Probl Surg. 31 (2): 77–156. PMID 7904550.
- ↑ O'Toole D, Delle Fave G, Jensen RT (2012). "Gastric and duodenal neuroendocrine tumours". Best Pract Res Clin Gastroenterol. 26 (6): 719–35. doi:10.1016/j.bpg.2013.01.002. PMID 23582915.
- ↑ "Gastrinoma - StatPearls - NCBI Bookshelf".
- ↑ Epelboym I, Mazeh H (2014). "Zollinger-Ellison syndrome: classical considerations and current controversies". Oncologist. 19 (1): 44–50. doi:10.1634/theoncologist.2013-0369. PMC 3903066. PMID 24319020.